October 09, 2024 Following Rep. Schiff, Sen. Smith’s Urging, CMS to Expand PrEP Coverage Under Medicare. Washington, D.C.— ...

Gilead is looking towards approval of lenacapavir as HIV PrEP after reporting near-perfect efficacy in the PURPOSE-1 and ...

People at risk for contracting HIV from sex can reduce their risk of infection by up to 99% when they take pre-exposure ...

ViiV Healthcare to triple annual supply of long-acting HIV PrEP for low- and middle-income countries: London, UK Wednesday, October 9, 2024, 12:00 Hrs [IST] GSK plc announced that ...

ViiV Healthcare has announced plans to triple its annual supply of long-acting cabotegravir for HIV pre-exposure prophylaxis ...

HHS breaks some notable new ground by proposing to account for receipt of HIV pre-exposure prophylaxis (PrEP) when ...

Gilead Sciences is granting licenses to six companies to produce lenacapavir for pre-exposure prophylaxis, as well as for ...

Alabama State University partnered with ViiV Healthcare during its 2024 Homecoming to address HIV prevention and awareness.

An emergency department (ED) opt-out testing strategy led to big increases in syphilis screening and diagnosis in the Chicago ...

GSK’s ViiV healthcare unit is countering rival HIV drugmaker Gilead’s recent global access moves with its own pledge to make at least 2 million doses of its long-acting pre-exposure prophylaxis (Pr | ...

Rabies has the dubious distinction of having the worst case fatality rate of any disease. The mortality rate is almost 100 ...

US antivirals specialist Gilead Sciences has released additional data from its pivotal Phase III PURPOSE 2 trial providing an ...